United States Biotechnology & Medical Research

Keros Therapeutics Inc (KROS)

Track

Over the past 90 days, Keros Therapeutics Inc. recorded 11 insider transactions, totaling $31,380 in purchases and $179,572 in sales. Activity included planned purchases by Jean-Jacques Bienaime and multiple planned sales by directors. These transactions follow a recent earnings report that missed expectations, amid a stock price decline of 8.7% over the last quarter.
Ticker: KROS Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Keros Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
BIENAIME JEAN JACQUES
1 purchase — total 100,000 USD
Planned buy 15 Jul 2026
Value US$451,462.68 | Price 286.12 | Shares 45,322
Planned buy 15 Jun 2026
Value US$2,574,365.59 | Price 197.90 | Shares 8,898
Planned sale 11 Jun 2026
Value US$5,522.00 | Price 10.04 | Shares 550
Proposed sale 11 Jun 2026
Value US$5,472.50 | Price 9.95 | Shares 550
Planned sale 4 Jun 2026
Value US$28,166.25 | Price 10.73 | Shares 2,625
Proposed sale 4 Jun 2026
Value US$28,035.00 | Price 10.68 | Shares 2,625
Planned sale 4 Jun 2026
Value US$28,166.25 | Price 10.73 | Shares 2,625
Proposed sale 4 Jun 2026
Value US$28,035.00 | Price 10.68 | Shares 2,625
Planned sale 4 Jun 2026
Value US$28,140.00 | Price 10.72 | Shares 2,625
Proposed sale 4 Jun 2026
Value US$28,035.00 | Price 10.68 | Shares 2,625
Planned buy 15 May 2026
Value US$10,580.00 | Price 10.58 | Shares 1,000
Planned buy 15 Apr 2026
Value US$11,700.00 | Price 11.70 | Shares 1,000
Proposed sale 31 Mar 2026
Value US$497,429.28 | Price 11.04 | Shares 45,057
Planned buy 9 Mar 2026
Value US$22,420.00 | Price 11.21 | Shares 2,000
Sale 19 Feb 2026
Value US$113,432.55 | Price 16.17 | Shares 7,015
Sale 18 Feb 2026
Value US$63,323.55 | Price 16.35 | Shares 3,873
Sale 18 Feb 2026
Value US$77,482.65 | Price 16.35 | Shares 4,739
Planned sale 18 Feb 2026
Value US$77,580.75 | Price 16.35 | Shares 4,745
Sale 15 Oct 2025
Value US$2,755,900.50 | Price 17.75 | Shares 155,262
Sale 15 Oct 2025
Value US$21,768,813.00 | Price 17.75 | Shares 1,226,412
Sale 15 Oct 2025
Value US$19,898,548.75 | Price 17.75 | Shares 1,121,045
Sale 15 Oct 2025
Value US$40,551,863.00 | Price 17.75 | Shares 2,284,612
Sale 15 Oct 2025
Value US$13,194,604.50 | Price 17.75 | Shares 743,358
Sale 15 Oct 2025
Value US$4,520,374.75 | Price 17.75 | Shares 254,669
Sale 15 Oct 2025
Value US$77,944,456.75 | Price 17.75 | Shares 4,391,237
Proposed sale 12 Sep 2025
Value US$1,340,157.26 | Price 15.71 | Shares 85,306
Buy 9 Apr 2025
Value US$767,859.89 | Price 10.33 | Shares 74,333
Buy 9 Apr 2025
Value US$5,165,000.00 | Price 10.33 | Shares 500,000
Buy 9 Apr 2025
Value US$3,203,525.00 | Price 9.86 | Shares 325,000
Buy 9 Apr 2025
Value US$153,752.45 | Price 9.40 | Shares 16,365
Buy 9 Apr 2025
Value US$174,374.91 | Price 9.40 | Shares 18,560
Sale 13 Aug 2024
Value US$1,293,894.00 | Price 44.01 | Shares 29,400
Sale 13 Aug 2024
Value US$9,708,606.00 | Price 44.01 | Shares 220,600
Sale 13 Aug 2024
Value US$1,293,894.00 | Price 44.01 | Shares 29,400
Sale 13 Aug 2024
Value US$9,708,606.00 | Price 44.01 | Shares 220,600
Proposed sale 13 Aug 2024
Value US$1,318,296.00 | Price 44.84 | Shares 29,400
Proposed sale 13 Aug 2024
Value US$9,891,704.00 | Price 44.84 | Shares 220,600
Proposed sale 4 Jan 2024
Value US$1,811,600.00 | Price 45.29 | Shares 40,000
Proposed sale 11 Dec 2023
Value US$8,769,900.00 | Price 35.65 | Shares 246,000
Planned sale 4 Nov 2023
Value US$1,811,600.00 | Price 45.29 | Shares 40,000
Proposed sale 12 Jun 2023
Value US$7,461,300.00 | Price 43.89 | Shares 170,000
Planned sale 9 Jun 2023
Value US$121,857.75 | Price 47.25 | Shares 2,579
Planned sale 9 Jun 2023
Value US$66,344.88 | Price 46.46 | Shares 1,428
Planned sale 9 Jun 2023
Value US$720,164.79 | Price 45.03 | Shares 15,993
Proposed sale 9 Jun 2023
Value US$908,322.00 | Price 45.42 | Shares 20,000
Planned sale 8 Jun 2023
Value US$131,306.35 | Price 48.65 | Shares 2,699
Planned sale 8 Jun 2023
Value US$824,565.66 | Price 47.66 | Shares 17,301
Proposed sale 8 Jun 2023
Value US$955,852.00 | Price 47.79 | Shares 20,000
Planned sale 15 Jul 2022
Value US$1,381,020.00 | Price 30.00 | Shares 46,034
Planned sale 13 Jul 2022
Value US$57,480.00 | Price 30.00 | Shares 1,916
Planned sale 11 May 2022
Value US$727.20 | Price 45.45 | Shares 16
Planned sale 11 May 2022
Value US$9,863.29 | Price 44.23 | Shares 223
Planned sale 11 May 2022
Value US$31,147.08 | Price 43.32 | Shares 719
Planned sale 11 May 2022
Value US$40,110.56 | Price 42.49 | Shares 944
Planned sale 11 May 2022
Value US$140,201.48 | Price 41.26 | Shares 3,398
Planned sale 11 Apr 2022
Value US$35,859.85 | Price 64.15 | Shares 559
Planned sale 11 Apr 2022
Value US$147,002.50 | Price 63.50 | Shares 2,315
Planned sale 11 Apr 2022
Value US$62,880.88 | Price 62.32 | Shares 1,009
Planned sale 11 Apr 2022
Value US$86,961.29 | Price 61.37 | Shares 1,417
Planned sale 6 Apr 2022
Value US$112,320.00 | Price 65.00 | Shares 1,728
Planned sale 4 Apr 2022
Value US$477,000.00 | Price 60.00 | Shares 7,950
Planned sale 1 Apr 2022
Value US$6,177.15 | Price 58.83 | Shares 105
Planned sale 1 Apr 2022
Value US$21,217.02 | Price 57.97 | Shares 366
Planned sale 1 Apr 2022
Value US$16,327.43 | Price 56.89 | Shares 287
Planned sale 1 Apr 2022
Value US$5,844.80 | Price 56.20 | Shares 104
Planned sale 1 Apr 2022
Value US$108.68 | Price 54.34 | Shares 2
Planned sale 11 Mar 2022
Value US$47,722.50 | Price 54.54 | Shares 875
Planned sale 11 Mar 2022
Value US$38,045.68 | Price 53.36 | Shares 713
Planned sale 11 Mar 2022
Value US$55,680.66 | Price 52.43 | Shares 1,062
Planned sale 11 Feb 2022
Value US$10,566.90 | Price 53.10 | Shares 199
Planned sale 11 Feb 2022
Value US$72,138.30 | Price 52.35 | Shares 1,378
Planned sale 11 Feb 2022
Value US$55,259.50 | Price 51.50 | Shares 1,073
Planned sale 11 Jan 2022
Value US$61,746.30 | Price 54.45 | Shares 1,134
Planned sale 11 Jan 2022
Value US$64,057.76 | Price 53.56 | Shares 1,196
Planned sale 11 Jan 2022
Value US$16,643.20 | Price 52.01 | Shares 320
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-17 2026-07-15 PP Planned purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
45,322 -14.6%
286.12
US$451,463 		45,322 -14.6% 286.12 US$451,463
2026-06-17 2026-06-15 PP Planned purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
8,898 -25.1%
197.90
US$2,574,366 		8,898 -25.1% 197.90 US$2,574,366
2026-06-15 2026-06-11 PlS Planned sale
1.5
Newton Charles W.
Non-Executive Director
9,658 +8.4%
175.64
US$3,719,933 		9,658 +8.4% 175.64 US$3,719,933
2026-06-11 2026-06-11 PrS Proposed sale
1.5
Newton Charles W.

Director

Non-Executive Director
550
9.95
US$5,472 		550 9.95 US$5,472
2026-06-08 2026-06-04 PlS Planned sale
Farzan Nima
Non-Executive Director
2,625 -21.2%
10.73
US$28,166 		2,625 -21.2% 10.73 US$28,166
2026-06-08 2026-06-04 PlS Planned sale
3.3
Knowles Julius
Non-Executive Director
2,625 -19.3%
10.73
US$28,166 		2,625 -19.3% 10.73 US$28,166
2026-06-05 2026-06-04 PlS Planned sale
1.3
Seth Alpna
Non-Executive Director
2,625 -21.2%
10.72
US$28,140 		2,625 -21.2% 10.72 US$28,140
2026-06-04 2026-06-04 PrS Proposed sale
Farzan Nima

Director

Non-Executive Director
2,625
10.68
US$28,035 		2,625 10.68 US$28,035
2026-06-04 2026-06-04 PrS Proposed sale
1.3
Seth Alpna

Director

Non-Executive Director
2,625
10.68
US$28,035 		2,625 10.68 US$28,035
2026-06-04 2026-06-04 PrS Proposed sale
3.3
Knowles Julius

Director

Non-Executive Director
2,625
10.68
US$28,035 		2,625 10.68 US$28,035
2026-05-19 2026-05-15 PP Planned purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +11.8%
10.58
US$10,580 		1,000 +11.8% 10.58 US$10,580
2026-04-17 2026-04-15 PP Planned purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 +13.4%
11.70
US$11,700 		1,000 +13.4% 11.70 US$11,700
2026-03-31 2026-03-31 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, LP

Shareholder; Director

Non-Executive Director
45,057
11.04
US$497,429 		45,057 11.04 US$497,429
2026-03-11 2026-03-09 PP Planned purchase
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
2,000 +36.7%
11.21
US$22,420 		2,000 +36.7% 11.21 US$22,420
2026-02-20 2026-02-19 S Sale
3.3
Seehra Jasbir

CHIEF EXECUTIVE OFFICER

Executive Director
7,015 -1.8%
16.17
US$113,433 		7,015 -1.8% 16.17 US$113,433
2026-02-20 2026-02-18 S Sale
3.3
Lerner Lorena Raquel

Chief Science Officer

Officer
3,873 -11.1%
16.35
US$63,324 		3,873 -11.1% 16.35 US$63,324
2026-02-20 2026-02-18 S Sale
3.3
Regnante Keith

CHIEF FINANCIAL OFFICER

Officer
4,739 -10.8%
16.35
US$77,483 		4,739 -10.8% 16.35 US$77,483
2026-02-20 2026-02-18 PlS Planned sale
Cho Esther

SVP, General Counsel

Officer
4,745 -10.7%
16.35
US$77,581 		4,745 -10.7% 16.35 US$77,581
2025-10-17 2025-10-15 S Sale
0.6
Pontifax Management 4 G.P. (2015) Ltd.
Large shareholder
155,262 -100.0%
17.75
US$2,755,900 		155,262 -100.0% 17.75 US$2,755,900
2025-10-17 2025-10-15 S Sale
0.6
Pontifax Management 4 G.P. (2015) Ltd.
Large shareholder
1,226,412 -100.0%
17.75
US$21,768,813 		1,226,412 -100.0% 17.75 US$21,768,813
2025-10-17 2025-10-15 S Sale
0.6
Pontifax Management 4 G.P. (2015) Ltd.
Large shareholder
1,121,045 -100.0%
17.75
US$19,898,549 		1,121,045 -100.0% 17.75 US$19,898,549
2025-10-17 2025-10-15 S Sale
0.6
Pontifax Management 4 G.P. (2015) Ltd.
Large shareholder
2,284,612 -100.0%
17.75
US$40,551,863 		2,284,612 -100.0% 17.75 US$40,551,863
2025-10-15 2025-10-15 S Sale
3.9
ADAR1 Capital Management, LLC
Large shareholder
743,358 -100.0%
17.75
US$13,194,604 		743,358 -100.0% 17.75 US$13,194,604
2025-10-15 2025-10-15 S Sale
3.9
ADAR1 Capital Management, LLC
Large shareholder
254,669 -100.0%
17.75
US$4,520,375 		254,669 -100.0% 17.75 US$4,520,375
2025-10-15 2025-10-15 S Sale
3.9
ADAR1 Capital Management, LLC
Large shareholder
4,391,237 -100.0%
17.75
US$77,944,457 		4,391,237 -100.0% 17.75 US$77,944,457
2025-09-12 2025-09-12 PrS Proposed sale
Rovaldi Christopher

Affiliate
85,306
15.71
US$1,340,157 		85,306 15.71 US$1,340,157
2025-04-11 2025-04-09 B Purchase
3.9
ADAR1 Capital Management, LLC
Large shareholder
74,333 +1.7%
10.33
US$767,860 		74,333 +1.7% 10.33 US$767,860
2025-04-11 2025-04-09 B Purchase
3.9
ADAR1 Capital Management, LLC
Large shareholder
500,000 +13.1%
10.33
US$5,165,000 		500,000 +13.1% 10.33 US$5,165,000
2025-04-11 2025-04-09 B Purchase
3.9
ADAR1 Capital Management, LLC
Large shareholder
325,000 +9.3%
9.86
US$3,203,525 		325,000 +9.3% 9.86 US$3,203,525
2025-04-11 2025-04-09 B Purchase
3.9
ADAR1 Capital Management, LLC
Large shareholder
16,365 +2.3%
9.40
US$153,752 		16,365 +2.3% 9.40 US$153,752
2025-04-11 2025-04-09 B Purchase
3.9
ADAR1 Capital Management, LLC
Large shareholder
18,560 +0.5%
9.40
US$174,375 		18,560 +0.5% 9.40 US$174,375
2024-08-15 2024-08-13 S Sale
1.5
GORDON CARL L
Non-Executive Director
29,400 -19.7%
44.01
US$1,293,894 		29,400 -19.7% 44.01 US$1,293,894
2024-08-15 2024-08-13 S Sale
1.5
GORDON CARL L
Non-Executive Director
220,600 -19.7%
44.01
US$9,708,606 		220,600 -19.7% 44.01 US$9,708,606
2024-08-15 2024-08-13 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
29,400 -19.7%
44.01
US$1,293,894 		29,400 -19.7% 44.01 US$1,293,894
2024-08-15 2024-08-13 S Sale
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
220,600 -19.7%
44.01
US$9,708,606 		220,600 -19.7% 44.01 US$9,708,606
2024-08-13 2024-08-13 PrS Proposed sale
2.6
OrbiMed Genesis Master Fund, LP

Shareholder; Director

Non-Executive Director
29,400
44.84
US$1,318,296 		29,400 44.84 US$1,318,296
2024-08-13 2024-08-13 PrS Proposed sale
2.6
OrbiMed Private Investments VII, LP

Shareholder; Director

Non-Executive Director
220,600
44.84
US$9,891,704 		220,600 44.84 US$9,891,704
2024-01-04 2024-01-04 PrS Proposed sale
3.3
Regnante Keith

Officer

Officer
40,000
45.29
US$1,811,600 		40,000 45.29 US$1,811,600
2023-12-11 2023-12-11 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
246,000
35.65
US$8,769,900 		246,000 35.65 US$8,769,900
2024-01-08 2023-11-04 PlS Planned sale
3.3
Regnante Keith

Chief Financial Officer

Officer
40,000 -100.0%
45.29
US$1,811,600 		40,000 -100.0% 45.29 US$1,811,600
2023-06-12 2023-06-12 PrS Proposed sale
The Biotech Growth Trust PLC

Shareholder
170,000
43.89
US$7,461,300 		170,000 43.89 US$7,461,300
2023-06-12 2023-06-09 PlS Planned sale
3.3
Regnante Keith

Chief Financial Officer

Officer
2,579 -100.0%
47.25
US$121,858 		2,579 -100.0% 47.25 US$121,858
2023-06-12 2023-06-09 PlS Planned sale
3.3
Regnante Keith

Chief Financial Officer

Officer
1,428 -35.6%
46.46
US$66,345 		1,428 -35.6% 46.46 US$66,345
2023-06-12 2023-06-09 PlS Planned sale
3.3
Regnante Keith

Chief Financial Officer

Officer
15,993 -80.0%
45.03
US$720,165 		15,993 -80.0% 45.03 US$720,165
2023-06-09 2023-06-09 PrS Proposed sale
3.3
Regnante Keith

Officer

Officer
20,000
45.42
US$908,322 		20,000 45.42 US$908,322
2023-06-12 2023-06-08 PlS Planned sale
3.3
Regnante Keith

Chief Financial Officer

Officer
2,699 -100.0%
48.65
US$131,306 		2,699 -100.0% 48.65 US$131,306
2023-06-12 2023-06-08 PlS Planned sale
3.3
Regnante Keith

Chief Financial Officer

Officer
17,301 -86.5%
47.66
US$824,566 		17,301 -86.5% 47.66 US$824,566
2023-06-08 2023-06-08 PrS Proposed sale
3.3
Regnante Keith

Officer

Officer
20,000
47.79
US$955,852 		20,000 47.79 US$955,852
2022-07-19 2022-07-15 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
46,034 -32.6%
30.00
US$1,381,020 		46,034 -32.6% 30.00 US$1,381,020
2022-07-15 2022-07-13 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
1,916 -2.0%
30.00
US$57,480 		1,916 -2.0% 30.00 US$57,480
2022-05-13 2022-05-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
16 -0.0%
45.45
US$727 		16 -0.0% 45.45 US$727
2022-05-13 2022-05-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
223 -0.3%
44.23
US$9,863 		223 -0.3% 44.23 US$9,863
2022-05-13 2022-05-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
719 -0.8%
43.32
US$31,147 		719 -0.8% 43.32 US$31,147
2022-05-13 2022-05-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
944 -1.1%
42.49
US$40,111 		944 -1.1% 42.49 US$40,111
2022-05-13 2022-05-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
3,398 -3.7%
41.26
US$140,201 		3,398 -3.7% 41.26 US$140,201
2022-04-13 2022-04-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
559 -0.6%
64.15
US$35,860 		559 -0.6% 64.15 US$35,860
2022-04-13 2022-04-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
2,315 -2.6%
63.50
US$147,002 		2,315 -2.6% 63.50 US$147,002
2022-04-13 2022-04-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
1,009 -1.1%
62.32
US$62,881 		1,009 -1.1% 62.32 US$62,881
2022-04-13 2022-04-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
1,417 -1.6%
61.37
US$86,961 		1,417 -1.6% 61.37 US$86,961
2022-04-08 2022-04-06 PlS Planned sale
Rovaldi Christopher

Chief Operating Officer

Officer
1,728 -100.0%
65.00
US$112,320 		1,728 -100.0% 65.00 US$112,320
2022-04-06 2022-04-04 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
7,950 -8.5%
60.00
US$477,000 		7,950 -8.5% 60.00 US$477,000
2022-04-05 2022-04-01 PlS Planned sale
Rovaldi Christopher

Chief Operating Officer

Officer
105 -100.0%
58.83
US$6,177 		105 -100.0% 58.83 US$6,177
2022-04-05 2022-04-01 PlS Planned sale
Rovaldi Christopher

Chief Operating Officer

Officer
366 -77.7%
57.97
US$21,217 		366 -77.7% 57.97 US$21,217
2022-04-05 2022-04-01 PlS Planned sale
Rovaldi Christopher

Chief Operating Officer

Officer
287 -37.9%
56.89
US$16,327 		287 -37.9% 56.89 US$16,327
2022-04-05 2022-04-01 PlS Planned sale
Rovaldi Christopher

Chief Operating Officer

Officer
104 -12.1%
56.20
US$5,845 		104 -12.1% 56.20 US$5,845
2022-04-05 2022-04-01 PlS Planned sale
Rovaldi Christopher

Chief Operating Officer

Officer
2 -0.2%
54.34
US$109 		2 -0.2% 54.34 US$109
2022-03-15 2022-03-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
875 -1.0%
54.54
US$47,722 		875 -1.0% 54.54 US$47,722
2022-03-15 2022-03-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
713 -0.8%
53.36
US$38,046 		713 -0.8% 53.36 US$38,046
2022-03-15 2022-03-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
1,062 -1.2%
52.43
US$55,681 		1,062 -1.2% 52.43 US$55,681
2022-02-15 2022-02-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
199 -0.2%
53.10
US$10,567 		199 -0.2% 53.10 US$10,567
2022-02-15 2022-02-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
1,378 -1.6%
52.35
US$72,138 		1,378 -1.6% 52.35 US$72,138
2022-02-15 2022-02-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
1,073 -1.2%
51.50
US$55,260 		1,073 -1.2% 51.50 US$55,260
2022-01-13 2022-01-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
1,134 -1.3%
54.45
US$61,746 		1,134 -1.3% 54.45 US$61,746
2022-01-13 2022-01-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
1,196 -1.4%
53.56
US$64,058 		1,196 -1.4% 53.56 US$64,058
2022-01-13 2022-01-11 PlS Planned sale
Lachey Jennifer

Chief Scientific Officer

Officer
320 -0.4%
52.01
US$16,643 		320 -0.4% 52.01 US$16,643
Explore more

More insider trading research around Keros Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America